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Pharmaceutical industry;
GXPsAbstract Objectives: The aim of this study is to:
a. Highlight the most important guidelines and practices of quality in the pharmaceutical
industry.
b. Organize such guidelines and practices to create a guide to pave the way for other
researchers who would like to dig deeper into these guidelines and practices.
Design: A review was conducted of 102 publications; 56 publications were concerned with
the pharmaceutical quality directly while 46 publications were concerned with the general quality
practices. The content of those sources was analyzed and the following themes were identiﬁed:
a. Research theme 1: Guidelines of the pharmaceutical quality.
b. Research theme 2: General practices recently applied in the pharmaceutical industry.
Main outcome measures: The following guidelines were identiﬁed and reviewed: WHO
guidelines, FDA guidelines, EU guidelines and ICH guidelines in the research theme I.
In research theme II; the following topics were identiﬁed and reviewed: quality risk management,
quality by design, corrective actions and preventive actions, process capability analysis, Six Sigma,
process analytical technology, lean manufacturing, total quality management, ISO series and
HACCP.
464 R.M. Haleem et al.Results: Upon reviewing the previously highlighted guidelines and the practices that are widely
applied in the pharmaceutical industry, it was noticed that there is an abundant number of papers
and articles that explain the general guidelines and practices but the literature lack those describing
application; case studies of the pharmaceutical factories applying those guidelines and signiﬁcance
of those guidelines and practices.
Conclusions: It is recommended that the literature would invest more in the area of application
and signiﬁcance of guidelines and practices. New case studies should be done to prove the feasibility
of such practices.
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The quality in the pharmaceutical industry has become a very
important topic. Since the world has gathered together to
harmonize its practices and guides and the launching of the
FDA current good manufacturing practices – the cGMP;
for the 21st century – there has been a growing awareness
for the signiﬁcance of the quality of the pharmaceutical prod-
ucts (Woodcock, 2004). This awareness is represented
through the appearance of several deﬁnitions deﬁning exactly
what the quality of the medicine should be (LEE and Webb,
2009). Many articles were written to demonstrate the special
nature of the product-customer relationship of medicine and
patients (Woodcock, 2004). Also the important role of gov-
ernments was emphasized through the joint statement be-
tween the international pharmaceutical federation; FIP; and
the international federation of pharmaceutical manufacturers
associations; IFPMA; to ensure the safety of medicinal prod-
ucts in order to protect the patient (FIP Council, 1999), pro-
viding that the pharmaceutical industry is one of the
most closely regulated industries for more than 50 years
(Woodcock, 2004).Since 2002, FDA began an initiative to address cGMP for
the 21st century (Woodcock, 2004). This effort involved taking
new looks at both the regulatory and industrial systems for
insuring drug quality (Larson, 2006).
A literature review was conducted on the quality in the
pharmaceutical industry, identifying 102 publications that
focus on conceptual issues, methodological issues, or the
application of different practices and/or guidelines applied in
the pharmaceutical industries. The content of these sources
was analyzed, and a number of themes were identiﬁed.
The literature review has two objectives concerned with the
quality guidelines and practices of the pharmaceutical industry
and the organization such as practices and guidelines to make
a guide for others to use.
A research of this kind serves to integrate past research and
can help current and future researchers, and practitioners
employing the suitable guideline or practice to develop their
methodological decisions in upgrading the industry.
This article introduced some issues regarding what is so
special about pharmaceutical quality and different drivers of
quality are then identiﬁed (Fraser, 2005; Dean and Bruttin,
2001). This is followed by the identiﬁed research themes and
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discussed.
2. Methods
A search was made of the following databases: WHO, FDA,
ICH, and EU to download their corresponding guidelines.
Using the Google search engine; also a number of papers
and articles were downloaded. Search words used were:
pharmaceutical quality, quality and pharmaceutical industry.
Papers that were not academic in nature were rejected (for
example, those that did not provide reference citations).
The ﬁnal sample consisted of 102 publications; 56 publica-
tions were related to the pharmaceutical quality directly while
46 publications were concerned with the general quality
practices.
Two research themes could be identiﬁed in the articles stud-
ied in this literature review.
They included:
 Guidelines of the pharmaceutical quality.
 General practices recently applied in the pharmaceuti-
cal industry.
For each of these research themes the authors synthesize
the main ﬁndings and offer suggestions for further research.
2.1. Research theme 1: guidelines of the pharmaceutical quality
The most important guidelines that are widely applied in the
pharmaceutical industry are:
2.1.1. WHO guidelines
WHO has published a handbook on the GMP in particular,
entitled: Quality assurance of pharmaceuticals, a compendium
of guidelines and related materials, Volume 2: good manufac-
turing practices and inspection (Quality Assurance of Pharma-
ceuticals, 2004).
It consists of 4 chapters:
Chapter 1: WHO GMP: main principles for pharmaceutical
products.
Chapter 2: Good manufacturing practices: starting
materials.
Chapter 3: Good manufacturing practices: speciﬁc pharma-
ceutical products.
Chapter 4: Inspection.
And 7 annexes:
Annex 3: Radiopharmaceutical products.
Annex 4: Good manufacturing practices for pharmaceutical
products: main principles.
Annex 5: Model Certiﬁcate of GMP.
Annex 6: Sterile pharmaceutical products.
Annex 6: Guidance on GMP inspection.
Annex 7: Pre-approval inspection.
Annex 8: Quality system requirements for national GMP
inspectorates.2.1.2. FDA guidelines
Pharmaceutical manufacturers have just begun to understand
and apply the FDA’s cGMPs for the 21st century: A Risk-
Based Approach; the initiative outlines immediate, near and
longer-term stages that FDA believes will take two years to
be implemented (Larson 2004).
On the technical side, FDA states three concepts that will
guide the reevaluation process: advances in risk management
science, advances in quality management science and advances
in pharmaceutical science and manufacturing technology
(Larson, 2004).
The most important guidelines are Code of Federal
Regulation 210, 211.
21CFR Part 210: The regulations contain the minimum
current good manufacturing practice for methods to be used
in, and the facilities or controls to be used for, the manufac-
ture, processing, packing, or holding of a drug to assure that
such a drug meets the requirements of the act as to safety,
and has the identity and strength and meets the quality and
purity characteristics that it claims to possess.
21CFR Part 211: The regulations in this part contain the
minimum current good manufacturing practice for prepara-
tion of drug products for administration to humans or
animals.
The FDA has concluded that modern quality systems to-
gether with manufacturing processes and product knowledge,
can handle many types of changes to facilities, equipment
and processes without the need for regulatory submission
(Fraser, 2005).
2.1.3. EU guidelines
The core of European Union legislation in the pharmaceutical
sector is gathered in Volume 1 and Volume 5 of the publica-
tion; ‘‘The rules governing medicinal products in the European
Union’’.
 Volume 1 – EU pharmaceutical legislation for medicinal
products for human use.
 Volume 5 – EU pharmaceutical legislation for medicinal
products for veterinary use.
The basic legislation is supported by a series of guidelines
that are also published in the following volumes of ‘‘The rules
governing medicinal products in the European Union’’:
 Volume 2 – Notice to applicants and regulatory guide-
lines for medicinal products for human use.
 Volume 3 – Scientiﬁc guidelines for medicinal products
for human use.
 Volume 4 – Guidelines for good manufacturing practices
for medicinal products for human and veterinary use.
 Volume 6 – Notice to applicants and regulatory guide-
lines for medicinal products for veterinary use.
 Volume 7 – Scientiﬁc guidelines for medicinal products
for veterinary use.
 Volume 8 – Maximum residue limits.
 Volume 9 – Guidelines for pharmacovigilance for medic-
inal products for human and veterinary use.
 Volume 10 – Guidelines for clinical trial.
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The International Conference on Harmonization of technical
requirements for registration of pharmaceuticals for human
use (ICH) is a special project that gathers the regulatory
authorities of Europe, Japan and the United States and experts
from the pharmaceutical industry in the three different regions;
to discuss scientiﬁc and technical aspects of product
registration.
The objective of such harmonization is a more efﬁcient use
of human, animal and material resources, and the removal of
any delay that is not essential in the global development and
availability of new medicines while maintaining safeguards
on quality, safety and efﬁcacy, and regulatory obligations to
protect public health.
2.2. Research theme 2: general practices recently applied in the
pharmaceutical industry
2.2.1. Quality risk management
All products and all processes have an inherent element of risk
(Grifﬁth, 2004).
In an organization that is intending to apply an effective
quality risk management approach, a clear deﬁnition of what
is considered ’’risk’’ should be agreed upon because of the
too many stakeholders in the pharmaceutical industry and
their corresponding diverse interests (ICH Q9, 2003).
The FDA has noticed that it needs to reorganize its proce-
dures and processes to merge the use of risk management pro-
grams (RMP) within the agency and within the industries it
regulates. Consequently, the FDA has started publishing posi-
tion papers and guidelines on what it expects to see in an RMP
(Grifﬁth, 2004).
Risk management plans should be used to identify risk
(Grifﬁth 2004).
Quality Risk Management is deﬁned as a method for the
assessment, control, communication and review of risks to
the quality of the drug (medicinal) product through the prod-
uct lifecycle where decisions can occur at any point in the pro-
cess (ICH Q9, 2003).
In the guideline entitled Medical Device Use-Safety: incor-
porating human factors engineering into risk management; it
clariﬁes how hazards related to medical device use should be
directed during device development as part of the risk manage-
ment process (CDRH, 2000).
2.2.2. Quality by design
ICH Q8 deﬁnes design space from the concept that quality
cannot be tested into product but has to be built in by design
(ICH Q8, 2005–2008).
Based on the ICH Q8; which concerns pharmaceutical
development with targeting designing quality into the ingredi-
ents, formulation and manufacturing process to deliver the in-
tended performance of the product. Design space is presented
by the applicant and is subject to regulatory assessment and
approval (ICH Q8, 2005–2008).
In these situations, opportunities exist to develop more ﬂex-
ible regulatory approaches.
The design and conduct of pharmaceutical development re-
search should be consistent with their intended scientiﬁc pur-
pose (ICH Q8, 2005–2008).2.2.3. Corrective action and preventive actions
QMS nonconformities and other system deﬁciencies, including
legal noncompliance, should be analyzed to detect patterns or
trends. Identifying trends allows the manufacturer to antici-
pate and prevent future problems (EPA, 2009).
The organization should focus on correcting and preventing
problems. Preventing problems is generally cheaper than ﬁxing
them after they occur. The organization should also start think-
ing about problems as opportunities to improve (EPA, 2009).
‘‘Root cause analysis’’ is a process by which the manufac-
turer can identify causes and preventive actions (EPA, 2009).
In general, CAPA experts recommend that root-cause
investigations follow a four-step process (Bartholomew, 2006):
 Identify the problem.
 Evaluate its magnitude, which includes assessing risk.
 Investigate and assign responsibility.
 Analyze and document the root cause of the problem.
For example a new corrective action tracking system had
helped Alcon Laboratories Inc. unite its many corrective and
preventive action systems worldwide resulting in faster time
of closure on corrective action, both access and speed to infor-
mation are much greater and ﬁnally quality professionals are
able to focus on more important issues (Davis, 2003).
2.2.4. Process capability analysis
Process capability is the comparison of the ‘‘Voice of the Cus-
tomer’’ (VOC) with the ‘‘Voice of the Process’’ (VOP). VOC,
which is built on customer requirements, is deﬁned by the spec-
iﬁcation limits of the process, which are ﬁxed, while VOP is de-
ﬁned by control limits, which are based on performance data
and vary over time (Tarpley, 2004).
Metrics such as capability index namely Cp and Cpk were
developed several years ago to calculate this comparison be-
tween control and speciﬁcation limits (Tarpley, 2004).
The capability index a ratio that compares process spread
to tolerance spread and results in a single number. It is a man-
agement tool which is used to compare process performance
(Ruth II, 2005).
2.2.5. Six Sigma
Harry and Schroeder (2000) deﬁne Six Sigma as ‘‘. . .a business
process that enables companies to increase proﬁts dramatically
by streamlining operations, improving quality, and eliminating
defects or mistakes in everything a company does. . ..’’ It can
help an organization reduce defects and improve proﬁtability
using several basic tenets (Harry and Schroeder, 2000; Johnson
and Swisher, 2003; Pande et al., 2000; Williams 2003; Goeke
and Offodile, 2005)
Six Sigma Projects are based on the DMAIC model
(Stamatis, 2002).
The DMAIC model is the generic model of six sigma meth-
odology. It is an acronym that stands for; Deﬁne, Measure,
Analyze, Improve and Control. Sometimes this model includes
recognize as an awareness item to the model. Each of the com-
ponents addresses a different aspect of the overall improve-
ment and breakthrough strategy (Stamatis, 2002).
The pharmaceutical industry sigma level is from 2 to 3; this
results in a 25–35% defects (Hussain, 2005).
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methodology of Six Sigma is AstraZeneca where the opera-
tions and quality staff were trained to apply DMAIC princi-
ples every day, to measure and improve performance
through cross-functional ‘‘continuous improvement’’ (CI)
teams (Shanley, 2005). Two years ago, at Westborough, Mas-
sachusetts, cross-functional CI teams involving QA, engineer-
ing and operations applied DMAIC principles to solve a major
capacity problem for a key product. The teams discovered
wasteful processes, effectively adding 20 million extra units
of capacity per year. Where a capital investment of less than
$100,000 led to $60 million to $70 million in revenue gains,
without hiring new staff as Ron Matthews, vice president
of manufacturing and supply chain at the company, said
(Shanley, 2005).
2.2.6. Process analytical technologies
Process analytical technologies (PAT); play a key role in en-
abling ‘‘quality by design’’ and scientiﬁc aspect of manufactur-
ing. PAT’s main aim is to understand and control the
manufacturing process through the application of integrated
chemical, physical, microbiological, mathematical and risk
analysis methods. PAT has been applied in non-Pharma indus-
tries for many years, yielding cost savings and manufacturing
efﬁciencies (Fraser, 2005).
The implementation of process analytical technology (PAT)
is bringing lots of beneﬁts and improvements for many phar-
maceutical processes. The beneﬁts are lower production cycle
times, improved manufacturing efﬁciency, reduced rejects
and increased production operating time (Rockwell Automation,
2004).
Within pharmaceutical industry, there have been a number
of successful PAT-based comparability protocol submissions,
ranging from single-unit operation application at Glaxo-
SmithKline to a more all-including application covering bothTable 1 ICH categories and main topics.
Q: Quality Topics
Those relating to chemical and pharmaceutical Quality Assurance:
(1) Stability
(2) Analytical Validation
(3) Impurities
(4) Pharmacopoeias
(5) Quality of Biotechnological Products
(6) Speciﬁcations
(7) Good Manufacturing Practice
(8) Pharmaceutical Development
(9) Risk Management
E: Eﬃciency Topics
Those relating to clinical studies in human subject
(1) Clinical Safety
(2) Clinical Study Reports
(3) Dose-Response Studies
(4) Ethnic Factors
(5) Good Clinical Practice
(6) Clinical Trials
(7) Guidelines for Clinical Evaluation by Therapeutic Category
(8) Clinical Evaluation
* Medical Dictionary for Regulatory Activities Terminology.drug substance and drug product at Sanoﬁ-Aventis (Shanley,
2005).
2.2.7. Lean manufacturing
Japanese manufacturers re-building after the Second World
War were facing declining human, material, and ﬁnancial re-
sources. These circumstances led to the development of new,
lower cost, manufacturing practices. Early Japanese leaders
such as the Toyota Motor Company’s Eiji Toyoda, Taiichi
Ohno, and Shingeo Shingo developed a disciplined, process-fo-
cused production system now known as the ‘‘Toyota Produc-
tion System’’, or ‘‘lean production.’’ The objective of this
system was to minimize the consumption of resources that
added no value to a product (Womack et al., 1990).
Lean manufacturing is about eliminating waste across an
entire company and focusing on the big picture through learn-
ing how to do more with less (Nystuen, 2002).
Lean means putting the right things in the right place at the
right time the ﬁrst time while minimizing waste and being open
to change. This leads to less waste, less design time, fewer orga-
nizational layers, and fewer suppliers with more employee
empowerment, more ﬂexibility and capability, more productiv-
ity, more customer satisfaction and without a doubt, more
long-term competitive success. Lean principles incorporated
in the workplace today can spell business survival for the fu-
ture (Nave, 2002).
In AstraZeneca; rather than being submerged into Lean,
the company launched a limited initiative at its global facilities
in 2002 which is the Pull Manufacturing; this initiative re-
quired that the company’s manufacturing teams shift their fo-
cus from output to customer alignment and service. Also, the
initiative has lead to reduction in the cycle time. In one case, it
allowed lead time for a key $1.5-billion-per year product to be
reduced by 25% during a period when demand for the drug
was increasing by 30% (Shanley, 2005) (see Table 1).S: Safety Topics
(1) Those relating to in vitro and in vivo pre-clinical studies
(2) Carcinogenicity Studies
(3) Genotoxicity Studies
(4) Toxicokinetics and Pharmacokinetics
(5) Toxicity Testing
(6) Reproductive Toxicology
(7) Biotechnological Products
(8) Pharmacology Studies
(9) Immuno-toxicology Studies
(10) Joint Safety/Efﬁcacy (Multidisciplinary) Topic
M: Multidisciplinary Topics
They are Cross-cutting topics, which do not ﬁt uniquely into one
of the above categories.
 M1: Medical Terminology (MedDRA)*
 M2: Electronic Standards for Transmission of Regulatory
Information (ESTRI)
 M3: Timing of Pre-clinical Studies in Relation to Clinical Trials
 M4: The Common Technical Document (CTD)
 M5: Data Elements and Standards for Drug Dictionaries
Table 2 The cost of system improvements in Lilly.
Control system improvement % Of savings gained % Of overall cost of control system
Implementation of regulatory control systems and basic hardware 20 70
The use of advanced control procedures such as feed forward and model based 75 80
The application of optimization methods to the process 100 100
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with some nonconformance and variability in product quality,
the application of lean lead to system improvement and cost
savings as shown in the following Table 2 (Mohan, 2006).
2.2.8. Total quality management
Total quality management (TQM) is a concept rather than a
technique. It is a philosophy that stresses a systematic, inte-
grated, and consistent perspective that would involve everyone
and everything in the organization (Isaac et al., 2004).
TQM is a management philosophy that builds a customer
driven, learning organization that is devoted to the total cus-
tomer satisfaction through continuous improvement in the
effectiveness and efﬁciency of the organization and its corre-
sponding processes (Corrigan, 1995).
TQM is widely known for improving quality and other per-
formances such as productivity, proﬁt, market share, and com-
petitive edge of organizations of various types (Sun, 2000;
Isaac et al., 2004).
2.2.9. ISO series
ISO 9000 series: ISO 9000 is concerned with ‘‘quality manage-
ment’’. This means what the organization does to increase cus-
tomer satisfaction through meeting customer and regulatory
requirements and continually improving its performance
(ISO 9000 and 14001 in brief, 2009).
ISO 14000: ISO 14000 is an environmental management
system, describes the requirements for an organization’s envi-
ronmental management system and can be used for certiﬁca-
tion/registration and/or self declaration of an organization’s
environmental management system (ISO 14001, 2004).
This means what the organization does to (ISO 9000 and
14001 in brief, 2009):
 Minimize harmful effects on the environment caused
by its activities.
 Achieve continual improvement of its environmental
performance.
ISO 17025: It gives the general requirements for the compe-
tence of testing and calibration laboratories (ISO/IEC 17025,
2005).
A speciﬁc version of this standard for Medical Laboratories
has been developed; ISO 15189:2003 then ISO 15189, 2007 was
published on 19th April 2007 (ISO 15189, 2007).
Through the accreditation process; the testing laboratory
reaches the status of an independent institution (Mettler-
Toledo GmbH, 2003).
2.2.10. HACCP
The Hazard Analysis and Critical Control Point (HACCP)
methodology was known to be a safety management systemused in the food industry. Their main aim is to prevent known
hazards and to reduce the risks that they will cause at speciﬁc
points in the food chain (Annex 7; WHO TRS No. 908, 2003).
Procedures, including GMP, address operational conditions
and provide the basis for HACCP. HACCP is a systematic
method for the identiﬁcation, assessment and control of safety
hazards. The hazards are classiﬁed as biological, chemical, or
physical agents or operations that might cause illness or injury
if not controlled. In the manufacture of pharmaceuticals, this
includes the manufacture of certain antibiotics, hormones,
cytotoxic substances or other highly active pharmaceuticals.
Together with operations such as ﬂuid bed drying, granulation
is an example of hazard unit operations. The use of inﬂamma-
ble solvents (solutions) and certain laboratory operations may
also produce hazards (Annex 7; WHO TRS No. 908, 2003).
The HACCP system is based on seven principles (Annex 7;
WHO TRS No. 908, 2003):
 Conduct a hazard analysis.
 Determine the critical control points (CCPs).
 Establish target levels and critical limit(s).
 Establish a system to monitor the CCPs.
 Establish the corrective action to be taken when mon-
itoring indicates that a particular CCP is not under
control.
 Establish procedures to verify that the HACCP system
is working effectively.
 Establish documentation concerning all procedures
and keep records appropriate to these principles and
their application.
3. Results
Upon reviewing the previously highlighted guidelines and the
practices that are widely applied in the pharmaceutical indus-
try, it was noticed that there is an abundant number of papers
and articles that explain the general guidelines and practices
but the literature lack those describing application; case studies
of the pharmaceutical factories applying those guidelines and
signiﬁcance of those guidelines and practices.
4. Discussions
It is recommended that the literature would invest more in the
area of application and signiﬁcance of guidelines and practices.
Also, there are some new practices that are recently applied
to the pharmaceutical industry though they are widely applied
in non pharmaceutical industries, such as: the lean manufac-
turing; the Six Sigma; the total quality management. Both
managers at the pharmaceutical industry and literature should
focus on the adoption of such practices into the pharmaceuti-
cal industry making use of the previous research in the
Quality in the pharmaceutical industry – A literature review 469non-pharmaceutical industry application. New case studies
should be done to prove the feasibility of such practices.
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